



ALK
Investor Relations Department
BÃge Alle 6-8
Horsholm DK-2970
Denmark

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

OMX: ALKB

Last Trade:	959.50
Trade Time:	4:59 PM ET Jul 25, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	839.00 - 1176.00
Volume	854,200

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

ALK is the world leader in allergy vaccination (immunotherapy). It is the goal of ALK to increase the awareness of the company and its activities through a structured, ongoing, timely and balanced dialogue with investors, shareholders and other stakeholders. It is also a company goal to secure the liquidity of the company's shares and to generate reasonable, long-term returns to shareholders through share price increases and dividends.... [\(more\)](#)

Company releases [\[View all \]](#)

Jun 1, 2017
[Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer](#)

Jun 1, 2017
[Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff](#)

May 9, 2017
[Three-month interim report \(Q1\) 2017](#)

May 4, 2017
[ALK's HDM SLIT-tablet, ACARIZAX®, approved in Canada](#)

May 3, 2017
[Release date of three-month interim report \(Q1\) 2017 and audio cast](#)

Upcoming Events [\[View all \]](#)

Aug 16, 2017
[Six-month interim report \(Q2\) 2017](#)

Sep 8, 2017
[Goldman Sachs Annual Biotech Symposium, London](#)